Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives
Frederik A. Verburg,Holger Amthauer,Ina Binse,Ingo Brink,Andreas Buck,Andreas Darr,Christine Dierks,Christine Koch,Ute König,Michael C. Kreissl,Markus Luster,Christoph Reuter,Klemens Scheidhauer,Holger Sven Willenberg,Andreas Zielke,Matthias Schott,Frederik A. Verburg,Holger Amthauer,Ina Binse,Ingo Brink,Andreas Buck,Andreas Darr,Christine Dierks,Christine Koch,Ute König,Michael C. Kreissl,Markus Luster,Christoph Reuter,Klemens Scheidhauer,Holger Sven Willenberg,Andreas Zielke,Matthias Schott
DOI: https://doi.org/10.1055/a-1380-4154
2021-03-01
Hormone and Metabolic Research
Abstract:Abstract Notwithstanding regulatory approval of lenvatinib and sorafenib to treat radioiodine-refractory differentiated thyroid carcinoma (RAI-R DTC), important questions and controversies persist regarding this use of these tyrosine kinase inhibitors (TKIs). RAI-R DTC experts from German tertiary referral centers convened to identify and explore such issues; this paper summarizes their discussions. One challenge is determining when to start TKI therapy. Decision-making should be shared between patients and multidisciplinary caregivers, and should consider tumor size/burden, growth rate, and site(s), the key drivers of RAI-R DTC morbidity and mortality, along with current and projected tumor-related symptomatology, co-morbidities, and performance status. Another question involves choice of first-line TKIs. Currently, lenvatinib is generally preferred, due to greater increase in progression-free survival versus placebo treatment and higher response rate in its pivotal trial versus that of sorafenib; additionally, in those studies, lenvatinib but not sorafenib showed overall survival benefit in subgroup analysis. Whether recommended maximum or lower TKI starting doses better balance anti-tumor effects versus tolerability is also unresolved. Exploratory analyses of lenvatinib pivotal study data suggest dose-response effects, possibly favoring higher dosing; however, results are awaited of a prospective comparison of lenvatinib starting regimens. Some controversy surrounds determination of net therapeutic benefit, the key criterion for continuing TKI therapy: if tolerability is acceptable, overall disease control may justify further treatment despite limited but manageable progression. Future research should assess potential guideposts for starting TKIs; fine-tune dosing strategies and further characterize antitumor efficacy; and evaluate interventions to prevent and/or treat TKI toxicity, particularly palmar-plantar erythrodysesthesia and fatigue.
endocrinology & metabolism